Revelation Biosciences (REVB) Competitors $2.67 -0.09 (-3.12%) As of 03:39 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock REVB vs. ATNF, AIMD, SYBX, EDSA, MBRX, MTEX, CYCC, LSB, HOTH, and LPCNShould you be buying Revelation Biosciences stock or one of its competitors? The main competitors of Revelation Biosciences include 180 Life Sciences (ATNF), Ainos (AIMD), Synlogic (SYBX), Edesa Biotech (EDSA), Moleculin Biotech (MBRX), Mannatech (MTEX), Cyclacel Pharmaceuticals (CYCC), LakeShore Biopharma (LSB), Hoth Therapeutics (HOTH), and Lipocine (LPCN). These companies are all part of the "pharmaceutical products" industry. Revelation Biosciences vs. Its Competitors 180 Life Sciences Ainos Synlogic Edesa Biotech Moleculin Biotech Mannatech Cyclacel Pharmaceuticals LakeShore Biopharma Hoth Therapeutics Lipocine Revelation Biosciences (NASDAQ:REVB) and 180 Life Sciences (NASDAQ:ATNF) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations. Is REVB or ATNF more profitable? 180 Life Sciences' return on equity of -141.25% beat Revelation Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Revelation BiosciencesN/A -240.27% -148.95% 180 Life Sciences N/A -141.25%-80.77% Do institutionals & insiders have more ownership in REVB or ATNF? 12.8% of Revelation Biosciences shares are owned by institutional investors. Comparatively, 4.1% of 180 Life Sciences shares are owned by institutional investors. 2.3% of Revelation Biosciences shares are owned by insiders. Comparatively, 38.2% of 180 Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has preferable valuation and earnings, REVB or ATNF? 180 Life Sciences is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRevelation BiosciencesN/AN/A-$15.04M-$68.61-0.04180 Life SciencesN/AN/A-$6.17M-$15.07-0.19 Does the media favor REVB or ATNF? In the previous week, Revelation Biosciences and Revelation Biosciences both had 1 articles in the media. 180 Life Sciences' average media sentiment score of 1.87 beat Revelation Biosciences' score of 0.94 indicating that 180 Life Sciences is being referred to more favorably in the news media. Company Overall Sentiment Revelation Biosciences Positive 180 Life Sciences Very Positive Which has more volatility and risk, REVB or ATNF? Revelation Biosciences has a beta of -0.05, meaning that its share price is 105% less volatile than the S&P 500. Comparatively, 180 Life Sciences has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500. Summary180 Life Sciences beats Revelation Biosciences on 7 of the 9 factors compared between the two stocks. Get Revelation Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for REVB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding REVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart REVB vs. The Competition Export to ExcelMetricRevelation BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.51M$3.09B$5.68B$9.65BDividend YieldN/A2.28%6.66%4.53%P/E Ratio-0.0420.9382.6326.32Price / SalesN/A395.10533.52210.95Price / CashN/A43.5325.6628.92Price / Book0.309.9111.296.04Net Income-$15.04M-$54.01M$3.27B$265.75M7 Day Performance-4.16%-0.24%0.04%-0.35%1 Month Performance9.59%9.02%8.20%5.55%1 Year Performance-95.16%7.53%54.16%17.44% Revelation Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)REVBRevelation Biosciences0.9485 of 5 stars$2.67-3.1%N/A-95.0%$4.51MN/A-0.0410Gap DownATNF180 Life Sciences0.9049 of 5 stars$3.08-6.8%N/A+55.2%$18.57MN/A-0.207Positive NewsAIMDAinos1.3657 of 5 stars$3.81-0.8%N/A+19.4%$17.76M$20K-0.7640Positive NewsShort Interest ↑Gap DownSYBXSynlogic1.059 of 5 stars$1.49+0.7%N/A-1.4%$17.43M$10K-18.6380Positive NewsEDSAEdesa Biotech1.5646 of 5 stars$2.45+1.2%$5.00+104.1%-47.6%$17.21MN/A-1.8520Positive NewsGap UpMBRXMoleculin Biotech3.0743 of 5 stars$0.56-2.1%$4.00+610.5%-84.6%$17.05MN/A0.0020MTEXMannatech0.8944 of 5 stars$8.93+7.2%N/A+22.0%$16.97M$117.87M-4.38250Positive NewsShort Interest ↑Gap DownCYCCCyclacel Pharmaceuticals1.0541 of 5 stars$7.55flatN/A-96.7%$16.88M$40K-0.0114Positive NewsShort Interest ↓LSBLakeShore Biopharma1.2378 of 5 stars$0.81-1.5%N/A-81.3%$16.78M$614.96M0.00773Short Interest ↓Gap UpHOTHHoth Therapeutics3.0757 of 5 stars$1.24-0.8%$4.00+222.6%+67.2%$16.51MN/A-1.164News CoveragePositive NewsGap UpLPCNLipocine2.5639 of 5 stars$3.05+0.8%$9.00+195.6%-20.7%$16.50M$11.20M-3.5010 Related Companies and Tools Related Companies 180 Life Sciences Competitors Ainos Competitors Synlogic Competitors Edesa Biotech Competitors Moleculin Biotech Competitors Mannatech Competitors Cyclacel Pharmaceuticals Competitors LakeShore Biopharma Competitors Hoth Therapeutics Competitors Lipocine Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:REVB) was last updated on 9/2/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revelation Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revelation Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
